Skip to main content
Supplement Research and Comparison WebsiteBest Price Guarantee
Supplement Research and Comparison Website

Study Design

Type
Clinical Trial
Population
Mice
Methods
In vivo and in vitro experimental study
  • Animal Study

Abstract

In the present study, we examined whether Lactobacillus johnsonii CJLJ103 (LJ) could alleviate cholinergic memory impairment in mice. Oral administration of LJ alleviated scopolamine-induced memory impairment in passive avoidance and Y-maze tasks. Furthermore, LJ treatment increased scopolamine-suppressed BDNF expression and CREB phosphorylation in the hippocampi of the brain, as well as suppressed TNF-α expression and NF-κB activation. LJ also increased BDNF expression in corticosterone-stimulated SH-SY5Y cells and inhibited NF-κB activation in LPS-stimulated microglial BV2 cells. However, LJ did not inhibit acetylcholinesterase activity. These findings suggest that LJ, a member of human gut microbiota, may mitigate cholinergic memory impairment by increasing BDNF expression and inhibiting NF-κB activation.

Keywords: BDNF; Lactobacillus johnsonii; NF-κB; memory impairment.

Research Insights

SupplementDoseHealth OutcomeEffect TypeEffect SizeSource
Lactobacillus johnsonii LJ09Enhanced Brain-Derived Neurotrophic Factor LevelsBeneficial
Moderate
View source

LJ treatment increased scopolamine-suppressed BDNF expression and CREB phosphorylation in the hippocampi of the brain.

Lactobacillus johnsonii LJ09Improved Memory FunctionBeneficial
Moderate
View source

Oral administration of LJ alleviated scopolamine-induced memory impairment in passive avoidance and Y-maze tasks.

Back to top